Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models

For the creation of a successful antibody–drug conjugate (ADC), both scientific and clinical evidence has indicated that highly toxic anticancer agents (ACA) should be conjugated to a monoclonal antibody (mAb) to administer a reasonable amount of ADC to patients without compromising the affinity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yoshiyuki, Hyodo, Ichinosuke, Koga, Yoshikatsu, Tsumura, Ryo, Sato, Ryuta, Obonai, Toshihumi, Fuchigami, Hirobumi, Furuya, Fumiaki, Yasunaga, Masahiro, Harada, Mitsunori, Kato, Yasuki, Ohtsu, Atsushi, Matsumura, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452165/
https://www.ncbi.nlm.nih.gov/pubmed/25711681
http://dx.doi.org/10.1111/cas.12645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452165/
https://www.ncbi.nlm.nih.gov/pubmed/25711681
http://dx.doi.org/10.1111/cas.12645

Ejemplares similares